Stockreport

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts [Read more]